Yayıncı "Future Medicine Ltd" Tıp Fakültesi için listeleme

Toplam kayıt 2, listelenen: 1-2

    • In Vitro And In Vivo Fitness Costs Associated With Mycobacterium Tuberculosis Rpob Mutation H526D 

      Rifat, Dalin; Campodnico, Victoria L.; Tao, Jing; Miller, James A.; Alp, Alpaslan; Yao, Yufeng; Karakousis, Petros C. (Future Medicine Ltd, 2017)
      Aim: There is controversy regarding the potential fitness costs of rifampicin (RIF) resistance-conferring mutations in the Mycobacterium tuberculosis (Mtb) rpoB gene. We characterized the pathogenicity of an Mtb RpoB H526D ...

    • Personalized Treatment is Better Than One Treatment Fits All in the Management of Patients with Mcrc: A Consensus Statement 

      Yalcin, Suayib; Trad, Diaeddine; Kader, Yasser Abdel; Halawani, Hafez; Demir, Osman Gokhan; Mall, Riaz; Meshcheryakov, Andrey; Nasr, Fadi; Nosworthy, Adam; Osinsky, Dmitry; Tumanova, Assel; Turhal, Serdar; Tejpar, Sabine; Koehne, Claus-Henning (Future Medicine Ltd, 2014)
      The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). ...